I agree that this site is using cookies. You can find further informations here.
X
Lalezari, Jacob
104  results:
Search for persons X
?
1

Long-term open-label vebicorvir for chronic HBV infection: ..:

Yuen, Man-Fung ; Fung, Scott ; Ma, Xiaoli...
JHEP Reports.  6 (2024)  4 - p. 100999 , 2024
Link: https://doi.org/10.1016/..
 
?
2

365. Durable efficacy and robust CD4+ T-cell count improvem..:

Dyson, Alftan ; Aberg, Judith A ; Molina, Jean-Michel...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
3

EDP-514 in healthy subjects and nucleos(t)ide reverse trans..:

Feld, Jordan J ; Lawitz, Eric ; Nguyen, Tuan...
Antiviral Therapy.  27 (2022)  6 - p. 135965352211278 , 2022
Link: https://doi.org/10.1177/..
 
?
4

Antiviral activity and safety of the hepatitis B core inhib..:

Yuen, Man-Fung ; Agarwal, Kosh ; Ma, Xiaoli...
Journal of Hepatology.  73 (2020)  - p. S140 , 2020
Link: https://doi.org/10.1016/..
 
?
5

Antiviral activity and safety of the hepatitis B core inhib..:

Fung, Scott ; Sulkowski, Mark ; Lalezari, Jacob...
Journal of Hepatology.  73 (2020)  - p. S51-S52 , 2020
Link: https://doi.org/10.1016/..
 
?
6

Antiviral Activity, Safety, and Pharmacokinetics of Capsid ..:

Yuen, Man Fung ; Gane, Edward J. ; Kim, Dong Joon...
Gastroenterology.  156 (2019)  5 - p. 1392-1403.e7 , 2019
Link: https://doi.org/10.1053/..
 
?
7

LBO-06-Interim safety and efficacy results of the ABI-H0731..:

Ma, Xiaoli ; Lalezari, Jacob ; Nguyen, Tuan...
Journal of Hepatology.  70 (2019)  1 - p. e130 , 2019
Link: https://doi.org/10.1016/..
 
?
8

MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or ..:

Poordad, Fred ; Pol, Stanislas ; Asatryan, Armen...
Gastroenterology.  152 (2017)  5 - p. S1057 , 2017
Link: https://doi.org/10.1016/..
 
?
9

TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and ..:

Wyles, David ; Saag, Michael ; Viani, Rolando M....
The Journal of Infectious Diseases.  215 (2017)  4 - p. 599-605 , 2017
Link: https://doi.org/10.1093/..
 
?
10

TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and ..:

Wyles, David ; Saag, Michael ; Viani, Rolando M....
The Journal of Infectious Diseases.  215 (2017)  4 - p. 599-605 , 2017
Link: http://www.jstor.org/sta..
 
?
11

Su1416 Safety of ABT-493 and ABT-530 Co-Administered in Pat..:

Kwo, Paul Y. ; Poordad, Fred ; Porcalla, Ariel R....
Gastroenterology.  150 (2016)  4 - p. S1093 , 2016
Link: https://doi.org/10.1016/..
 
?
12

High Efficacy of ABT-493 and ABT-530 Treatment in Patients ..:

Gane, Edward ; Poordad, Fred ; Wang, Stanley...
Gastroenterology.  151 (2016)  4 - p. 651-659.e1 , 2016
Link: https://doi.org/10.1053/..
 
?
13

Primary Efficacy Endpoint and Safety Results of Ibalizumab ..:

Lalezari, Jacob ; Fessel, W. Jeffery ; Schrader, Shannon...
Open Forum Infectious Diseases.  3 (2016)  suppl_1 - p. , 2016
Link: https://doi.org/10.1093/..
 
?
14

755 100% Svr4 and Favorable Safety of Abt-493 + Abt-530 Adm..:

Gane, Edward ; Lalezari, Jacob ; Asatryan, Armen...
Gastroenterology.  150 (2016)  4 - p. S1047 , 2016
Link: https://doi.org/10.1016/..
 
?
15

752 High SVR Rates With the Combination of ABT-493 + ABT-53..:

Poordad, Fred ; Felizarta, Franco ; Wang, Stanley...
Gastroenterology.  150 (2016)  4 - p. S1046-S1047 , 2016
Link: https://doi.org/10.1016/..
 
1-15